Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: State of the art

Drugs

Volumn 66, Issue 11, 2006, Pages 1441-1463

  Diasio, Robert B ^a   Fourie, Jeanne ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; MAB 806; MATUZUMAB; MDX 447; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PELITINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; TP 38; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

ANGIOGENESIS; ASTHENIA; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CHEMOTHERAPY; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG HALF LIFE; DRUG METABOLISM; FATIGUE; FEVER; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; INJECTION SITE REACTION; LEUKOPENIA; LUNG INJURY; LUNG NON SMALL CELL CANCER; MALAISE; METASTASIS; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; RASH; REVIEW; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ANTIBODIES; COLORECTAL NEOPLASMS; ENZYME INHIBITORS; HUMANS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33747340480     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666110-00003     Document Type: Review

References (244)

1. American Cancer Society. Cancer facts and figures 2006 [online]. Available from URL: http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf [Accessed 2006 Jul 24]
2. O'Connell JB, Maggard MA, Liu JH, et al. Rates of colon and rectal cancers are increasing in young adults. Am Surg 2003; 69 (10): 866-72
3. Kindler HL, Shulman KL. Metastatic colorectal cancer. Curr Treat Options Oncol 2001; 2 (6): 459-71
4. Pazdur R, Coia LR, Wagman LD, et al. Colorectal and anal cancers. In: Pazdur R, Coia LR, Hoskins WJ, et al., editors. Cancer management: a multidisciplinary approach. Melville (NY): PRR, 1999: 149-75
5. Saltz LB, Douillard JY, Pirotta N, et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 2001; 6 (1): 81-91
6. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21 (11): 2059-69
7. Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995; 13 (6): 1303-11
8. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22 (11): 2084-91
9. Cassidy J, Scheithauer W, McKendrick J, et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a phase III trial [abstract no. 3509]. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans (LA). J Clin Oncol 2004; 22: 247s
10. Grothe W, Arnold D, Peinert S, et al. Cetuximab with oxaliplatin and capecitabine (CAPOX) in patients with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy [abstract no. 3669]. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13-17; Orlando (FL). J Clin Oncol 2005; 23: 288s
11. Hoff PM, Pazdur R, Lassere Y, et al. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol 2004; 22 (11): 2078-83
12. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343 (13): 905-14
13. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22 (1): 23-30
14. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22 (2): 229-37
15. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350 (23): 2343-51
16. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100 (1): 57-70
17. Giantonio BJ, Levy D, O'Dwyer PJ, et al. Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (advCRC): results from the Eastern Cooperative Oncology Group (ECOG) Study E2200 [abstract no. 1024]. Proc Am Soc Clin Oncol 2003; 22: 255
18. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200 [abstract]. Program and abstracts of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium; 2005 Jan 27-29; Hollywood (FL), 169a
19. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23 (16): 3697-705
20. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22 (7): 1201-8
21. Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004; 58 (3): 984-90
22. Vanhoefer U, Tewes M, Rojo F, et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004; 22 (1): 175-84
23. Crombet T, Torres L, Neninger E, et al. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother 2003; 26 (2): 139-48
24. Johns TG, Stockert E, Ritter G, et al. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer 2002; 98 (3): 398-408
25. Wallace PK, Romet-Lemonne JL, Chokri M, et al. Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcgammaRI and the epidermal growth factor receptor. Cancer Immunol Immunother 2000; 49 (9): 493-503
26. Von Pawel J. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumours. Bull Cancer 2004; 91 (5): E70-6
27. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22 (1): 77-85
28. Park YW, Younes MN, Jasser SA, et al. AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice. Clin Cancer Res 2005; 11 (5): 1963-73
29. Nunes M, Shi C, Greenberger LM. Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes. Mol Cancer Ther 2004; 3 (1): 21-7
30. Zhou H, Kim YS, Peletier A, et al. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 2004; 58 (2): 344-52
31. Li B, Chang CM, Yuan M, et al. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res 2003; 63 (21): 7443-50
32. Murren JR, Papadimitrakopoulou VA, Sizer K, et al. A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PK1166, a novel tyrosine kinase inhibitor, in patients with advanced cancers [abstract no. 377]. Presented at the 38th Annual Meeting of the American Journal of Clinical Oncology; 2002 May 18-21; Orlando (FL). Proc Am Soc Clin Oncol 2002; 21: 95a
33. Miller KD, Trigo JM, Wheeler C, et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005; 11 (9): 3369-76
34. Sampson JH, Akabani G, Archer GE, et al. Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003; 65 (1): 27-35
35. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004; 102 (1): 37-46
36. Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31 (6): 637-43
37. Xu YH, Richert N, Ito S, et al. Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc Natl Acad Sci U S A 1984; 81 (23): 7308-12
38. Bafico A, Aaronson SA. Growth factors signal transduction in cancer. In: Kufe DW, Bast RC, Hait WN, et al., editors. Cancer medicine. Hamilton (ON): BC Decker Inc., 2006: 53-67
39. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990; 265 (14): 7709-12
40. Ullrich A, Coussens L, Hayflick JS, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984; 309 (5967): 418-25
41. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19 (3): 183-232
42. Jorissen RN, Walker F, Pouliot N, et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003; 284 (1): 31-53
43. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2 (2): 127-37
44. Bray D, Lay S. Computer simulated evolution of a network of cell-signaling molecules. Biophys J 1994; 66 (4): 972-7
45. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 1987; 56: 881-914
46. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001; 13 (6): 506-13
47. Pinkas-Kramarski R, Soussan L, Waterman H, et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996; 15 (10): 2452-67
48. Riese DJ, van Raaij TM, Plowman GD, et al. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol 1995; 15 (10): 5770-6
49. Schaeffer L, Duclert N, Huchet-Dymanus M, et al. Implication of a multisubunit Ets-related transcription factor in synaptic expression of the nicotinic acetylcholine receptor. EMBO J 1998; 17 (11): 3078-90
50. Prenzel N, Fischer OM, Streit S, et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001; 8 (1): 11-31
51. Rubin Grandis J, Zeng Q, Drenning SD. Epidermal growth factor receptor: mediated stat3 signaling blocks apoptosis in head and neck cancer. Laryngoscope 2000; 110 (5 Pt 1): 868-74
52. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004; 102 (1): 37-46
53. Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402 (6764): 884-8
54. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21 (14): 2787-99
55. Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5 (2): 257-65
56. Verbeek BS, Adriaansen-Slot SS, Vroom TM, et al. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett 1998; 425 (1): 145-50
57. Wells A. Tumor invasion: role of growth factor-induced cell motility. Adv Cancer Res 2000; 78: 31-101
58. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37 Suppl. 4: S3-8
59. Fischer-Colbrie J, Witt A, Heinzl H, et al. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 1997; 17 (1B): 613-9
60. Barker FG, Simmons ML, Chang SM, et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001; 51 (2): 410-8
61. Masuda M, Toh S, Koike K, et al. The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil. Jpn J Cancer Res 2002; 93 (3): 329-39
62. Downward J, Yarden Y, Mayes E, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984; 307 (5951): 521-7
63. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999; 17 (3): 259-69
64. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19 (13): 3159-67
65. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 2001; 8 (3): 161-73
66. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003; 284 (1): 99-110
67. Layfield LJ, Bernard PS, Goldstein NS. Color multiplex polymerase chain reaction for quantitative analysis of epidermal growth factor receptor genes in colorectal adenocarcinoma. J Surg Oncol 2003; 83 (4): 227-31
68. Kondo Y, Issa JP. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev 2004; 23 (1-2): 29-39
69. Mazelin L, Bernet A, Bonod-Bidaud C, et al. Netrin-1 controls colorectal tumorigenesis by regulating apoptosis. Nature 2004; 431 (7004): 80-4
70. Rubin Grandis J, Tweardy DJ, Melhem MF. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res 1998; 4 (1): 13-20
71. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90 (11): 824-32
72. Mezo I, Kovacs M, Szoke B, et al. New Gaba-containing analogues of human growth hormone-releasing hormone (1-30)-amide: I. Synthesis and in vitro biological activity. J Endocrinol Invest 1993; 16 (10): 793-8
73. Miller WE, Earp HS, Raab-Traub N. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol 1995; 69 (7): 4390-8
74. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001; 8 (2): 83-96
75. Bigner SH, Humphrey PA, Wong AJ, et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 1990; 50 (24): 8017-22
76. Humphrey PA, Gangarosa LM, Wong AJ, et al. Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function. Biochem Biophys Res Commun 1991; 178 (3): 1413-20
77. Pedersen MW, Meltorn M, Damstrup L, et al. The type III epidermal growth factor receptor mutation: biological significance and potential target for anti-cancer therapy. Ann Oncol 2001; 12 (6): 745-60
78. Wikstrand CJ, Hale LP, Batra SK, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995; 55 (14): 3140-8
79. Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor recept and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005; 11 (4): 1462-6
80. Bodey B, Kaiser HE, Siegel SE. Epidermal growth factor receptor (EGFR) expression in childhood brain tumours. In Vivo 2005; 19 (5): 931-41
81. Garcia de Palazzo I, Adams GP, Sundareshan P, et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 1993; 53 (14): 3217-20
82. Moscatello DK, Holgado-Madruga M, Godwin AK, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995 Dec; 55 (23): 5536-9
83. Ge H, Gong X, Tang CK. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer 2002; 98 (3): 357-61
84. Olapade-Olaopa EO, Moscatello DK, MacKay EH, et al. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer 2000; 82 (1): 186-94
85. Cunningham MP, Essapen S, Thomas H, et al. Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. Int J Oncol 2005; 27 (2): 317-25
86. Chu CT, Everiss KD, Wikstrand CJ, et al. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J 1997; 324 (Pt 3): 855-61
87. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350 (21): 2129-39
88. Paez JG, Janne PA, Lee JC, et al. EGFR Mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304 (5676): 1497-500
89. Wan CW, McKnight MK, Brattain DE, et al. Different epidermal growth factor growth responses and receptor levels in human colon carcinoma cell lines. Cancer Lett 1988; 43 (1-2): 139-43
90. Khalifa MA, Rowsell CH, Gladdy RA, et al. Expression of epidermal growth factor receptor in primary colorectal adenocarcinoma predicts expression in recurrent disease. Am J Clin Pathol 2006; 125 (2): 229-33
91. Vallbohmer D, Zhang W, Gordon M, et al. Molecular determinants of cetuximab efficacy. J Clin Oncol 2005; 23 (15): 3536-44
92. Yasui W, Sumiyoshi H, Hata J, et al. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res 1988; 48 (1): 137-41
93. Inada S, Koto T, Futami K, et al. Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today 1999; 29 (6): 493-503
94. Yoshida K, Kuniyasu H, Yasui W, et al. Expression of growth factors and their receptors in human esophageal carcinomas: regulation of expression by epidermal growth factor and transforming growth factor alpha. J Cancer Res Clin Oncol 1993; 119 (7): 401-7
95. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53 (15): 3579-84
96. Bunn PA. Treatment of advanced non-small-cell lung cancer with two-drug combinations. J Clin Oncol 2002; 20 (17): 3565-7
97. Wong AJ, Ruppert JM, Bigner SH, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 1992; 89 (7): 2965-9
98. Rubin Grandis J, Zeng Q, Tweardy DJ. Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines. Nat Med 1996; 2 (2): 237-40
99. Rubin Grandis J, Melhem MF, Barnes EL, et al. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996; 78 (6): 1284-92
100. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37 Suppl. 4: S9-15
101. Kim GE, Kim YB, Cho NH, et al. Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. Clin Cancer Res 2004; 10 (4): 1366-74
102. Gibault L, Metges JP, Conan-Charlet V, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 2005; 93 (1): 107-15
103. Walker RA, Dearing SJ. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat 1999; 53 (2): 167-76
104. Gamboa-Dominguez A, Dominguez-Fonseca C, Quintanilla-Martinez L, et al. Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system. Mod Pathol 2004; 17 (5): 579-87
105. Trikha M, Yan L, Nakada MT. Monoclonal antibodies as therapeutics in oncology. Curr Opin Biotechnol 2002; 13 (6): 609-14
106. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004; 5 (5): 292-302
107. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1 (2): 118-29
108. Burton DR, Woof JM. Human antibody effector function. Adv Immunol 1992; 51: 1-84
109. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus Irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Presented at the Annual Meeting of the American Society of Clinical Oncology; 2001 May 5-12; San Francisco (CA). Proc Am Soc Clin Oncol 2001; 20: 3a
110. Chu E. Cetuximab targeted therapy: a new treatment paradigm for advanced colorectal cancer. Clin Colorectal Cancer 2004; 3 (4): 205
111. Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1 (11): 1311-8
112. Needle MN. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin Oncol 2002; 29 (5 Suppl. 14): 55-60
113. Prewett M, Rockwell P, Rockwell RF, et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 1996; 19 (6): 419-27
114. Fan Z, Lu Y, Wu X, et al. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 1994; 269 (44): 27595-602
115. Prewett M, Rothman M, Waksal H, et al. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res 1998; 4 (12): 2957-66
116. Hadari YR, Doody JF, Wang Y, et al. The IgG1 monoclonal antibody cetuximab induces degradation of the epidermal growth factor receptor [abstract]. Program and abstracts of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium; 2004 Jan 22-24; San Francisco (CA), 234
117. Sunada H, Yu P, Peacock JS, et al. Modulation of tyrosine, serine, and threonine phosphorylation and intracellular processing of the epidermal growth factor receptor by antireceptor monoclonal antibody. J Cell Physiol 1990; 142 (2): 284-92
118. Kang X, Patel D, Shi J, et al. Anti-EGFR monoclonal antibody cetuximab binds the EGFR variant III receptor and internalizes phosphorylated receptor on the cell surface [abstract]. Eur J Cancer 2002; 38 (7): 149
119. Wu X, Rubin M, Fan Z, et al. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 1996; 12 (7): 1397-403
120. Karnes WE, Weller SG, Adjei PN, et al. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells. Gastroenterology 1998; 114 (5): 930-9
121. Peng D, Fan Z, Lu Y, et al. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 1996; 56 (16): 3666-9
122. Busse D, Doughty RS, Ramsey TT, et al. Reversible G (1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27 (KIP1) independent of MAPK activity. J Biol Chem 2000; 275 (10): 6987-95
123. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57 (21): 4838-48
124. Budillon A, Di Gennaro E, Barbarino M, et al. ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, upregulates P27KIP1 inducing G1 arrest and enhancing the antitumor effect of interferon alpha. Proc Am Assoc Cancer Res 2000; 41: 773
125. Wu X, Fan Z, Masui H, et al. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 1995; 95 (4): 1897-905
126. Mandal M, Adam L, Mendelsohn J, et al. Nuclear targeting of Bax during apoptosis in human colorectal cancer cells. Oncogene 1998; 17 (8): 999-1007
127. Liu B, Fang M, Schmidt M, et al. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br J Cancer 2000; 82 (12): 1991-9
128. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151 (6): 1523-30
129. Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000; 6 (5): 1936-48
130. Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001; 7 (5): 1459-65
131. O-charoenrat P, Rhys-Evans P, Modjtahedi H, et al. Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin Exp Metastasis 2000; 18 (2): 155-61
132. O-charoenrat P, Rhys-Evans P, Court WJ, et al. Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands. Clin Exp Metastasis 1999; 17 (7): 631-9
133. Matsumoto T, Perrotte P, Bar-Eli M, et al. Blockade of EGF-R signaling with anti-EGF-R monoclonal antibody (Mab) C225 inhibits matrix metalloproteinase-9 (MMP-9) expression and invasion of human transitional cell carcinoma (TCC) in vitro and in vivo [abstract]. Proc Am Assoc Cancer Res 1998; 39: 83
134. Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Barc) 2003; 39 Suppl. C: 1-16
135. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18 (4): 904-14
136. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19 (13): 3234-43
137. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351 (4): 337-45
138. Saltz J, Lenz H, Hochster H, et al. Randomized phase ii trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer [abstract no. 3508]. J Clin Oncol 2005; 23 (16 Suppl.): 248s
139. Diaz-Rubio E, Tabernero J, Van Cutsem E, et al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international phase II study [abstract no. 3535]. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13-17; Orlando (FL). J Clin Oncol 2005; 23: 254s
140. Kim ES, Mauer AM, Tran HT, et al. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: Final report [abstract no. 2581]. Proc Am Soc Clin Oncol 2003; 22: 642
141. Saltz LB, Lenz H-J, Kindler H, et al. Interim of randomized phase II trial if cetuximab/bevacizumab/irenotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer [abstract]. Program and abstracts of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium; 2005 Jan 27-29; Hollywood (FL), 169B
142. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23 (9): 1803-10
143. Lang I, Zaluski J, Changchien CR, et al. Cetuximab with irinotecan in first-line treatment of epidermal growth factor receptor (EGFR)-expressing metastic colorectal cancer (mCRC): preliminary safety results (CRYSTAL) [abstract no. 3555]. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; 2006 Jun 2-6; Atlanta (GA). J Clin Oncol 2006; 24: 18S
144. Bonner JA, Giralt J, Harari PM, et al.Cetuximab improves locoregional control and survival of locoregionally advanced head and neck cancer: independent review of mature data with a median follow-up of 45 months. 17th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2005 Nov 14; Philadelphia (PA), 153
145. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23 (24): 5578-87
146. Vermorken J, Bourhis J, Trigo J, et al. Cetuximab (Erbitux®) in recurrent/ metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies [abstract no. 5505]. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13-17; Orlando (FL). J Clin Oncol 2005; 23: 501s
147. Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 2004; 30 (3): 255-68
148. Cohen RB. Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer 2003; 2 (4): 246-51
149. Yang XD, Jia XC, Corvalan JR, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999; 59 (6): 1236-43
150. Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38 (1): 17-23
151. Hecht JR, Patnaik A, Malik I, et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis [abstract no. 3511]. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans (LA). J Clin Oncol 2004; 22: 247s
152. Malik I, Hecht JR, Patnaik A, et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC) [abstract no. 3520]. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13-17; Orlando (FL). J Clin Oncol 2005; 23 (Pt 1): 251s
153. Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22 (15): 3003-15
154. Crawford J, Sandler AB, Hammond LA, et al. ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC) [abstract no. 7083]. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13-17; Orlando (FL). J Clin Oncol 2005; 23 (Pt 1): 637s
155. Bier H, Hoffmann T, Hauser U, et al. Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother Pharmacol 2001; 47 (6): 519-24
156. Crombet T, Torres O, Rodriguez V, et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study. Hybridoma 2001; 20 (2): 131-6
157. Curnow RT. Clinical experience with CD64-directed immunotherapy: an overview. Cancer Immunol Immunother 1997; 45 (3-4): 210-5
158. Mishima K, Johns TG, Luwor RB, et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 2001; 61 (14): 5349-54
159. Fisher GA, Kuo T, Cho CD, et al. A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer [abstract no. 3514]. J Clin Oncol 2004; 22: 248s
160. Redlinger M, Kramer A, Flaherty K, et al. A phase II trial of gefitinib in combination with 5-FU/LV/irinotecan in patients with colorectal cancer [abstract no. 3767]. J Clin Oncol 2004; 22: 310s
161. Townsley C, Major P, Siu LL, et al. Phase II study of OSI-774 in patients with metastatic colorectal cancer [abstract no. 179]. Eur J Cancer 2002; 38: S57
162. Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 2003; 284 (1): 122-30
163. Dittmann K, Mayer C, Fehrenbacher B, et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 2005; 280 (35): 31182-9
164. AstraZeneca. Iressa® (gefitinib) product insert. 2004
165. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-46
166. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290 (16): 2149-58
167. Giaccone G, Johnson D, Scagliotti GV, et al. Results of a multivariate analysis of prognostic factors of overall survival of patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib (ZD1839) in combination with platinum-based chemotherapy (CT) in two large phase III trials (INTACT 1 and 2) [abstract no. 2522]. Presented at the 39th Annual Meeting of the American Society of Clinical Oncology; 2003 May 31-Jun 3; Chicago (IL). Proc Am Soc Clin Oncol 2003; 22: 627
168. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366 (9496): 1527-37
169. US Food and Drug Administration. FDA public health advisory: new labeling and distribution program for gefitinib (Iressa) [online]. Available from URL: http://www.fda.gov/cder/foi/label/2005/021339s008lbl.pdf [Accessed 2006 Jul 24]
170. Woodburn JR, Kendrew J, Fennell M, et al. ZD1839 ('Iressa') a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): inhibition of C-FOS MRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition [abstract no. 2552]. Proc Am Assoc Cancer Res 2000; 41: 402
171. Baselga J, Averbuch SD. ZD1839 ('Iressa') as an anticancer agent. Drugs 2000; 60 Suppl. 1: 33-40
172. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6 (5): 2053-63
173. Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6 (12): 4885-92
174. Anido J, Matar P, Albanell J, et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/ HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 2003; 9 (4): 1274-83
175. Woodburn JR, Barker AJ, Wakeling AE, et al. 6-amino-4-(3- methylphenylamino)-quinazoline: an EGF receptor tyrosine kinase inhibitor with activity in a range of human tumor xenografts [abstracts no. 2665]. Proc Am Assoc Cancer Res 1996; 37: 390
176. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20 (1): 110-24
177. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62 (20): 5749-54
178. Learn CA, Hartzell TL, Wikstrand CJ, et al. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 2004; 10 (9): 3216-24
179. Nishikawa R, Ji XD, Harmon RC, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 1994; 91 (16): 7727-31
180. Huang HS, Nagane M, Klingbeil CK, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997; 272 (5): 2927-35
181. Daneshmand M, Parolin DA, Hirte HW, et al. A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin Cancer Res 2003; 9 (7): 2457-64
182. Cohen EE, Rosen F, Dekker A, et al. Phase II study of ZD1839 (Iressa) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) [abstract no. 899]. Presented at the 38th Annual Meeting of the American Journal of Clinical Oncology; 2002 May 18-21; Orlando (FL). Proc Am Soc Clin Oncol 2002; 21: 225a
183. Drucker B, Bacik J, Ginsberg M, et al. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drugs 2003; 21 (3): 341-5
184. Dorligschaw O, Kegel T, Jordon K, et al. ZD 1839 (Iressa)-based treatment as last-line therapy in patients with advanced colorectal cancer (ACRC) [abstract no. 1494]. Presented at the 39th Annual Meeting of the American Journal of Clinical Oncology; 2003 May 31-Jun 3; Chicago (IL). Proc Am Soc Clin Oncol 2003; 22: 372
185. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004; 22 (1): 133-42
186. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial: INTACT 2. J Clin Oncol 2004; 22 (5): 785-94
187. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial: INTACT 1. J Clin Oncol 2004; 22 (5): 777-84
188. Blackledge G, Averbuch S. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer 2004; 90 (3): 566-72
189. Inomata S, Takahashi H, Nagata M, et al. Acute lung injury as an adverse event of gefitinib. Anticancer Drugs 2004; 15 (5): 461-7
190. Fisher GA, Kuo T, Cho CD, et al. A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer [abstract no. 3514]. J Clin Oncol 2004; 22: 14S
191. Kuo T, Cho CD, Halsey J, et al. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol 2005; 23 (24): 5613-9
192. Forero L, Patnaik A, Hammond LA, et al. Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin [abstract no. 1908]. Presented at the 38th Annual Meeting of the American Journal of Clinical Oncology; 2002 May 18-21; Orlando (FL). Proc Am Soc Clin Oncol 2002; 21: 25b
193. Malik SN, Siu LL, Rowinsky EK, et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 2003; 9 (7): 2478-86
194. Grunwald V, Hidalgo M. Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774). Adv Exp Med Biol 2003; 532: 235-46
195. Oza AM, Townsley CA, Siu LL, et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer [abstract no. 785]. Presented at the 39th Annual Meeting of the American Society of Clinical Oncology; 2003 May 31-Jun 3; Chicago (IL). Proc Am Soc Clin Oncol 2003; 22: 196
196. Meyerhardt JA, Xhu A, Enzinger PC, et al. Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC) [abstract no. 3580]. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans (LA). J Clin Oncol 2004; 22: 265s
197. Messersmith WA, Laheru DA, Senzer NN, et al. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res 2004; 10 (19): 6522-7
198. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353 (2): 123-32
199. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353 (2): 133-44
200. Casado E, Folprecht G, Paz-Ares L, et al. A phase I/IIA pharmacokinetic (PK) and serial skin and tumor pharmacodynamic (PD) study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) (FOLFIRI regimen) in patients (pts) with advanced colorectal cancer (ACC) [abstract no. 3543]. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans (LA). J Clin Oncol 2004; 22: 255s
201. Adams VR, Bence AK, Anderson EB, et al. A phase I pharmacokinetic/ pharmacodynamic study evaluating multiple doses of oral GW572016 in healthy patients [abstract no. 374]. Proc ASCO 2002; 21: 94a
202. DeSimone PA, Bence AK, Anderson EB, et al. A phase I study to investigate the safety, tolerability, and pharmacokinetics of single oral escalating doses of GW572016 in healthy volunteers [abstract no. 375]. Presented at the 38th Annual Meeting of the American Journal of Clinical Oncology; 2002 May 18-21; Orlando (FL). Proc Am Soc Clin Oncol 2002; 21: 94a
203. Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002; 21 (41): 6255-63
204. Bos M, Mendelsohn J, Kim YM, et al. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res 1997; 3 (11): 2099-106
205. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002; 7 Suppl. 4: 31-9
206. Ciardiello F, Tortora G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 2003; 39 (10): 1348-54
207. Imclone Systems Incorporated B-MSC. Erbitux™ (cetuximab). US prescribing information; Princeton (NJ): Imclone Systems Incorporated B-MSC, 2006
208. DakoCytomation. EGFR pharmDx™ package insert. 2004
209. Lenz HJ, Mayer RJ, Gold PJ, et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin [abstract no. 3510]. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans (LA). J Clin Oncol 2004; 22: 247s
210. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Rectal Cancer. Version 2.2006
211. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Colon Cancer. Version 2.2006
212. McLeod HL, Yu J. Cancer pharmacogenomics: SNPs, chips, and the individual patient. Cancer Invest 2003; 21 (4): 630-40
213. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21 (10): 1980-7
214. Ervin TJ, Toothaker SR. Community practice experience with gefitinib (ZD1839) as treatment for patients with advanced non-small-cell lung cancer (NSCLC) within an expanded access clinical program [abstract no. 7367]. J Clin Oncol 2004; 22: 14S
215. Saltz L, Rubin MS, Hochster H, et al. Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) [abstract]. Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2001 Oct 29-Nov 2; Miami Beach (FL), 559
216. Van Cutsem E, Mayer RJ, Gold P, et al. Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin [abstract]. Presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 2004 Sep 28-Oct 1; Geneva, 279
217. Lenz H, Mayer RJ, Gold P, et al. Activity of erbitux (cetuximab) in patients with colorectal cancer refractory to a fluoropyrimidine, irinotecan, and oxaliplatin [abstract]. Program and abstracts of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium; 2005 Jan 27-9; Hollywood (FL), 225
218. Chen HX, Mooney M, Boron M, et al. Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: an NCI Treatment Referral Center trial (TRC-0301) [abstract no. 3515]. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans (LA). J Clin Oncol 2004; 22: 248s
219. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350 (23): 2335-42
220. Huang S, Armstrong EA, Benavente S, et al. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004; 64 (15): 5355-62
221. Hainsworth JD, Sosman JA, Spigel DR, et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005; 23 (31): 7889-96
222. Azzariti A, Xu JM, Porcelli L, et al. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839). Biochem Pharmacol 2004; 68 (1): 135-44
223. Xu JM, Azzariti A, Severino M, et al. Characterization of sequence-dependent synergy between ZD1839 "Iressa" and oxaliplatin. Biochem Pharmacol 2003; 66 (4): 551-63
224. Xu JM, Azzariti A, Colucci G, et al. The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Cancer Chemother Pharmacol 2003; 52 (6): 442-8
225. Rosenberg AH, Loehrer P, Needle MN, et al. Erbitux (IMC-C255) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EFGr) [abstract no. 536]. Presented at the 38th Annual Meeting of the American Journal of Clinical Oncology; 2002 May 18-21; Orlando (FL). Proc Am Soc Clin Oncol 2002; 21: 135a
226. Schoffski P, Lutz MP, Folprecht G, et al. Cetuximab (C225) plus irinotecan (CPT-11) plus infusional 5FU-folinic acid (FA) is safe and active in metastatic colorectal cancer (MCRC), that expresses epidermal growth factor receptor (EGFR) [abstract no. 633]. Presented at the 38th Annual Meeting of the American Journal of Clinical Oncology; 2002 May 18-21; Orlando (FL). Proc Am Soc Clin Oncol 2002; 21: 159a
227. Saltz LB, Lenz H, Hochster H, et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer [abstract no. 3508]. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13-17; Orlando (FL). J Clin Oncol 2005; 23: 248s
228. Harari PM, Huang S, Li J, et al. Combining radiation with molecular blockade of the EGF receptor in cancer therapy [abstract no. 88]. Clin Cancer Res 1999 5 (11 Suppl.): 3747s
229. Saleh MN, Raisch KP, Stackhouse MA, et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm 1999; 14 (6): 451-63
230. Bonner JA, Giralt J, Harari PM, et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab [abstract no. 5507]. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans (LA). J Clin Oncol 2004; 22: 489s
231. Sinicrope FA, Gill S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev 2004; 23 (1-2): 63-75
232. Mann JR, Dubois RN. Cyclooxygenase-2 and gastrointestinal cancer. Cancer J 2004; 10 (3): 145-52
233. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69: 145-82
234. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107 (4): 1183-8
235. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995; 55 (17): 3785-9
236. Chang SH, Liu CH, Conway R, et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A 2004; 101 (2): 591-6
237. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122 (5): 518-23
238. Mann M, Sheng H, Shao J, et al. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001; 120 (7): 1713-9
239. Zahner G, Wolf G, Ayoub M, et al. Cyclooxygenase-2 overexpression inhibits platelet-derived growth factor-induced mesangial cell proliferation through induction of the tumor suppressor gene p53 and the cyclin-dependent kinase inhibitors p21waf-1/cip-1 and p27kip-1. J Biol Chem 2002; 277 (12): 9763-71
240. Papamichael D. Prognostic role of angiogenesis in colorectal cancer. Anticancer Res 2001; 21 (6B): 4349-53
241. Chen Z, Zhang X, Li M, et al. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 2004; 10 (17): 5930-9
242. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352 (11): 1071-80
243. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345 (6): 433-42
244. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351 (17): 1709-11